Highest-materiality recent filing
Xencor Q2 net loss $21.7M; Alexion settlement $105M; XmAb819 ESMO presentation
Q2 2026 revenue $51.2M (up from $43.6M YoY); net loss $21.7M ($0.29 loss per share) vs $30.8M loss in Q2 2025.
Xencor settles Ultomiris U.S. royalty dispute with Alexion for $105M
Xencor to receive $105M in two equal payments: $52.5M in Aug 2026 and $52.5M in July 2027.
Xencor reports Q1 net loss $128.9M ($1.71/shr); revenue down to $4.5M from $32.7M
Q1 2026 revenue $4.5M (vs $32.7M Q1 2025), including a $6.6M one-time reduction from Alexion royalty dispute.
XmAb942 achieved 74.1-day half-life; supports single SC dose every 12 weeks during maintenance.
Alexion refuses further US Ultomiris royalties; Xencor disputes, cuts revenue forecast
Alexion informed Xencor it will not pay additional US royalties on Ultomiris and will cease future US payments.
Xencor Q4 net loss narrows to $6.7M; XmAb819 dose expansion advances; Xtend royalty upside $100-120M
Q4 revenue $28.2M (down 47% YoY), full year $125.6M (up 14%). Net loss $6.7M ($0.09/sh) vs $45.6M prior-year Q4.
Xencor narrows Q3 net loss to $6M; advances key bispecific antibodies toward pivotal studies
Net loss $6.0M ($0.08 per share) vs $46.3M loss ($0.72) in Q3 2024; revenue $21.0M, up from $17.8M.
Xencor reports 25% ORR for XmAb819 in ccRCC Phase 1; dose-expansion cohort selected
XmAb819 (ENPP3 x CD3) Phase 1: 25% ORR (5/20 PRs) and 70% DCR in target dose range in heavily pre-treated ccRCC.
Xencor Q2 2025 revenue $43.6M, net loss $30.8M; Incyte milestone $25M
Revenue $43.6M (up from $23.9M Q2 2024); net loss $30.8M ($0.41/share) vs $67.3M ($1.09) prior year.
Xencor Q1 net loss narrows to $48.4M; CDO Valente resigns, Phase 2b UC study on track
Q1 revenue $32.7M (up from $16.0M YoY); net loss $48.4M (-$0.66 EPS) versus $73.4M (-$1.20 EPS) prior year.
Xencor reports positive interim Phase 1 results for XmAb942; half-life >71 days
XmAb942 well tolerated; no serious AEs, no discontinuations.
Xencor dismisses auditor RSM, appoints KPMG after material weaknesses and restatement
Dismissed RSM on Feb 27, 2025; engaged KPMG effective March 3, 2025.
Xencor dismisses RSM as auditor over material weaknesses; appoints KPMG
RSM dismissed Feb 27, 2025; KPMG appointed effective Mar 3, 2025.
Xencor Q4 net loss widens to $45.6M; full-year revenue falls 37% to $110.5M
Q4 revenue $52.8M (+3.5% YoY) driven by milestone payments; full-year revenue $110.5M vs $174.6M.
Xencor restates FY2023 and Q1-Q3 2024 results; errors in royalty accounting and tax
Royalty transaction with OMERS Life Sciences misclassified as deferred income instead of debt; impacted balance sheet by ~$168.5M debt understatement.
Xencor Q3 net loss $45.1M ($0.71 EPS), revenue down 82% YoY; cash $754M
Net loss of $45.1M ($0.71 diluted EPS) vs net loss of $24.3M ($0.40) in Q3 2023.
Xencor prices $175M public offering of common stock and pre-funded warrants
Offering of 6,635,112 shares at $18.00/share and pre-funded warrants for 3,088,888 shares at $17.99 each.
Xencor unveils autoimmune pipeline, reports initial XmAb819 RECIST responses in ccRCC
XmAb942 (anti-TL1A) Phase 1 healthy volunteer study starts Q4 2024; interim data in H1 2025.
Xencor Q2 net loss widens to $66M; revenue falls 63% YoY to $17M
Net loss $66.0M ($1.07 diluted EPS) vs $22.0M ($0.37) in Q2 2023; net loss $134M YTD.
Xencor Regains Exclusive Worldwide Rights to Plamotamab After Janssen Termination
Xencor regains worldwide rights to plamotamab, a CD20 x CD3 bispecific T-cell engager, after Janssen terminates its rights.
Xencor Q1 2024 net loss $68.0M ($1.11/share); revenue down to $12.8M from $19.0M
Net loss widened to $68.0M from $60.8M YoY; diluted EPS -$1.11 vs -$1.02.
Xencor Q4 2023 net loss $19.1M ($0.31 EPS); cash $697.4M; workforce cut ~10%
Q4 2023 revenue $44.7M vs $21.6M YoY; full-year net loss $126.1M ($2.08) vs $55.2M ($0.93) in 2022.
Xencor converts Genentech collaboration to royalty/milestone deal; up to $600M in milestones
New agreement replaces cost/profit-sharing with tiered royalties (low double-digit to mid-teens percent) starting June 1, 2024.
Xencor sells Ultomiris and Monjuvi royalty rights to OMERS for $215M upfront
OMERS pays $192.5M for Ultomiris royalties from July 2023 through end-2025, then annual caps starting in 2026.
Xencor receives $215M royalty payment, Q3 net loss $(0.40)/share; cash runway into 2027
Royalty transaction with OMERS yields $215M upfront for portions of Ultomiris and Monjuvi royalties; cash runway extended to 2027.
Xencor CFO John Kuch to retire in March 2024 after 23 years
John Kuch, SVP and CFO, notified Xencor of retirement effective March 31, 2024.
Xencor Q1 net loss of $60.8M vs prior-year net income; revenue down to $19.0M
Net loss of $60.8M ($1.02 diluted EPS) vs net income of $23.6M ($0.39 EPS) in Q1 2022.
Xencor appoints Nancy Valente as EVP, Chief Development Officer; board reduced to 7
Nancy Valente appointed EVP and Chief Development Officer effective May 1, 2023; she resigned from board.
Xencor enters into $200M ATM equity offering program with SVB Securities
Up to $200M of common stock may be sold at the market through SVB Securities under Sales Agreement dated Feb 27, 2023.
Xencor Q4 2022 net loss $12M vs net income $73.1M; revenue $21.6M down 86% YoY
Net loss per share $(0.20) vs EPS $1.21 in Q4 2021; full year net loss $55.2M.
Xencor Q3 net loss $32.8M ($0.55/sh); XmAb564 shows durable Treg expansion in Phase 1a
Q3 revenue $27.3M (up from $19.7M); net loss $32.8M vs $40.2M loss year ago.
On May 5, 2025, Nancy Valente, Executive Vice President and Chief Development Officer, notified the Company of her intention to resign from the Company effective June 6, 2025, and remain as a senior advisor.
Todd Simpson was appointed to serve as a new member of the Board of Directors (the “Board”) of Xencor, Inc. (the “Company”).
On September 30, 2024 Dagmar Rosa-Bjorkeson provided notice to the board of directors (the “Board”) of Xencor, Inc. (the “Company”) of her intent not to stand for reelection to the Board at the Company’s 2025 Annual Meeting of Stockholders.
Effective on April 9, 2024, Mr. Kuch will step down from his role as Chief Financial Officer of the Company.
on April 9, 2024 (the “Start Date”), Mr. Bart Cornelissen, age 46, was appointed as Senior Vice President and Chief Financial Officer of the Company for an indefinite term.
On October 24, 2023, John Kuch, Senior Vice President and Chief Financial Officer, notified Xencor, Inc. (the “Company”) of his intention to retire from the Company effective March 31, 2024.
On September 15, 2023, the Board of Directors of the Company (the “Board”) was increased from seven to eight board members and Barbara Klencke, M.D., was appointed to serve as a new member of the Board.
On April 26, 2023, Xencor, Inc. (the “Company”), announced that Dr. Allen Yang was stepping down from his role as an executive officer of the Company, effective as of May 1, 2023.
Dr. Nancy Valente tendered her offer of resignation from the Board of Directors (the "Board") of Xencor, Inc. (the "Company"), subject to the Board's acceptance of her resignation. Also on April 24, 2023, the Board accepted Dr. Valente's resignation, effective as of May 1, 2023.
Dr. Allen Yang will step down from his role as an executive officer of the Company. He will continue to be employed by the Company in a non-executive capacity.
Dr. Nancy Valente, age 64, was appointed as Executive Vice President and Chief Development Officer of the Company, effective May 1, 2023
On June 23, 2022, Yujiro S. Hata tendered his offer of resignation from the Board of Directors (the “Board”) of Xencor, Inc. (the “Company”), subject to the Board’s acceptance of his resignation. On September 8, 2022, the Board accepted Mr. Hata’s resignation.
Max materiality 0.90 · Median 0.65 · Most common event other_material